MORRIS REICHLIN, MD
Osteopathic Medicine at 13 St, Oklahoma City, OK
License number
Oklahoma 13067
Category
Osteopathic Medicine
Type
Allergy & Immunology
License number
Oklahoma 13067
Category
Osteopathic Medicine
Type
Rheumatology
Address
Address
825 NE 13Th St, Oklahoma City, OK 73104
Phone
(405) 271-7392
(405) 271-1515
(405) 271-1515
Personal information
See more information about MORRIS REICHLIN at radaris.comName
Address
Phone
5801 N Stonewall Dr, Oklahoma City, OK 73111
5801 Stonewall Dr, Oklahoma City, OK 73111
Professional information
Morris Reichlin, Oklahoma City OK
Specialties:
Internal Medicine, Allergy & Immunology, Rheumatology
Work:
Oklahoma Universtiy Physicians
825 NE 13Th St, Oklahoma City, OK 73104
825 NE 13Th St, Oklahoma City, OK 73104
Education:
Washington University at St. Louis (1959)
Method For Treatment Of Sle
US Patent:
6342218, Jan 29, 2002
Filed:
Feb 14, 1997
Appl. No.:
08/800682
Inventors:
Morris Reichlin - Oklahoma City OK
Eugen Koren - San Francisco CA
Eugen Koren - San Francisco CA
Assignee:
Oklahoma Medical Research Foundation - Oklahoma City OK
International Classification:
A61K 39395
US Classification:
4241311, 4241331, 4241921, 4241931, 514 12, 514 13, 514 14, 514 15, 514 16, 514 17, 514 18, 530324, 530325, 530326, 530327, 530328, 530329, 530330, 5303871, 530403
Abstract:
Treatments have been developed for lupus patients using either anti-ID antibodies to dsDNA to block anti-dsDNA antibodies and/or kill the B cells producing the anti-dsDNA antibodies or ribosomal protein S1 peptides immunoreactive with anti-dsDNA antibodies. Examples demonstrate that (1) anti-dsDNA antibodies are cross-reactive with ribosomal protein S1, (2) anti-dsDNA antibodies suppress protein synthesis, presumably through inhibition of mRNA translation initiation, and (3) a normal human sera contains an anti-idiotypic antibody (anti-Id) to anti-dsDNA antibodies isolated from SLE patients which blocked the interactions between the anti-Id antibody fragment (Fab ) and various anti-dsDNA preparations.
Morris Reichlin, Oklahoma City OK
Specialties:
Internist
Address:
825 Ne 13Th St, Oklahoma City, OK 73104
Method For Treatment Of Sle
US Patent:
2002015, Oct 24, 2002
Filed:
Jan 23, 2001
Appl. No.:
09/768155
Inventors:
Morris Reichlin - Oklahoma City OK, US
Eugen Koren - San Francisco CA, US
Eugen Koren - San Francisco CA, US
International Classification:
A61K039/395
US Classification:
424/131100
Abstract:
Treatments have been developed for lupus patients using either anti-ID antibodies to dsDNA to block anti-dsDNA antibodies and/or kill the B cells producing the anti-dsDNA antibodies or ribosomal protein S1 peptides immunoreactive with anti-dsDNA antibodies. Examples demonstrate that (1) anti-dsDNA antibodies are cross-reactive with ribosomal protein S1, (2) anti-dsDNA antibodies suppress protein synthesis, presumably through inhibition of mRNA translation initiation, and (3) a normal human sera contains an anti-idiotypic antibody (anti-Id) to anti-dsDNA antibodies isolated from SLE patients which blocked the interactions between the anti-Id antibody fragment (Fab) and various anti-dsDNA preparations.
Assay For Pathogenicity Of Anti-Dna Antibodies
US Patent:
6280944, Aug 28, 2001
Filed:
Aug 2, 1999
Appl. No.:
9/366103
Inventors:
Morris Reichlin - Oklahoma City OK
Eugen Koren - Oklahoma City OK
Wei Zhang - Oklahoma City OK
Eugen Koren - Oklahoma City OK
Wei Zhang - Oklahoma City OK
Assignee:
Oklahoma Medical Research Foundation - Oklahoma City OK
International Classification:
C12Q 168, G01N 3353, G01N 33567, G01N 33537, G01N 33543
US Classification:
435 6
Abstract:
Assays that are prognostic for patients that will develop nephritis have been developed where patient serum is screened for the presence of anti-dsDNA antibodies that are cross reactive with A and D SnRNP proteins. The assays are based on the use of either peptides containing epitopes bound by the anti-dsDNA antibodies, or the antigens for the antibodies, A and D SnRNP proteins. Therapeutic compositions have also been developed using either antibodies that block the pathogenicity of the anti-dsDNA antibodies, such as the naturally occurring anti-La/SSB, anti-Ro/SSA and anti-U. sub. 1 RNP antibodies that are cross reactive with the anti-dsDNA or using the peptides or A and D proteins to induce tolerance.
Assay For Pathogenicity Of Anti-Dna Antibodies
US Patent:
5681700, Oct 28, 1997
Filed:
May 25, 1994
Appl. No.:
8/249387
Inventors:
Morris Reichlin - Oklahoma City OK
Eugen Koren - Oklahoma City OK
Eugen Koren - Oklahoma City OK
Assignee:
Oklahoma Medical Research Foundation - Oklahoma City OK
International Classification:
G01N 3353
US Classification:
435 6
Abstract:
Assays that are prognostic for patients that will develop nephritis have been developed where patient serum is screened for the presence of anti-dsDNA antibodies that are cross reactive with A and D SnRNP proteins. The assays are based on the use of either peptides containing epitopes bound by the anti-dsDNA antibodies, or the antigens for the antibodies, A and D SnRNP proteins. Therapeutic compositions have also been developed using either antibodies that block the pathogenicity of the anti-dsDNA antibodies, such as the naturally occurring anti-La/SSB and anti-U. sub. 1 RNP antibodies that are cross reactive with the anti-dsDNA or using the peptides or A and D proteins to induce tolerance.